Boston Scientific data shows 'excellent' outcomes for Taxus stent in diabetics

By Elaine Rigoli

Tampa, Fla., June 12 - Boston Scientific Corp. announced the results from the independent, multi-center Stent registry, which it said it the largest prospective, comparative real-world drug-eluting stent study ever reported.

An analysis of data on diabetic patients revealed numerically favorable outcomes for the Taxus Express2 paclitaxel-eluting stent system compared to Johnson & Johnson's Cypher sirolimus-eluting stent system in reducing mortality rates and overall major adverse cardiovascular events (MACE), the company said in a news release.

The Stent registry included follow-up on 5,566 patients at eight coronary centers in the United States who received either a Taxus stent system or a Cypher stent system, including 1,680 diabetic patients, nearly 500 of whom were insulin-treated diabetics.

The new information included nine-month outcomes for all diabetic patients and nine-month death rates in insulin-treated patients, the release said.

Despite the higher complexity of the Taxus patients, the Taxus stent system demonstrated excellent outcomes in MACE when compared to the Cypher stent system in diabetic patients overall (6.8% versus 7.1%).

In addition, the rate of death was lower for Taxus (1.9% for Taxus versus 3.4% for Cypher) without reaching statistical significance, the release said.

Boston Scientific is a Natick, Mass.-based developer of medical devices whose products are used in a broad range of interventional medical specialties.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.